JPRN-UMIN000008888已完成未知
eoadjuvant radiation therapy concurrent with S-1 followed by systemic S-1/Gemcitabine therapy for Borderline resectable pancreatic cancer patients; A pilot study - The pilot study of neoadjuvant S1+RT followed by systemic GS therapy for Borderline resectable pancreatic cancer patients
Department of Surgical Oncology and Gastroenterological Surgery, Sapporo Medical University Hospital0 个研究点目标入组 30 人开始时间: 2012年9月14日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients who have previously administered S-1 or gemcitabine 2) Patients who have previous history of radiotherapy to the abdomen 3) Uncontrollable watery or chornic diarrhea 4) Regular use of frucitocin, fenitoin or warfarin 5) Patients who can' t receive neither iodic drug because of drug allergy 6) Lung fibrosis or interstitial pneumonia which accompanied by clinical symptoms or are evident in imaging findings 7) Massive pleural or abdominal effusion 8) Those with Active infectious diseases 9) Uncontrolled diabetes 10) Simultaneous or metachronous (within 3 years) double cancers 11) Hemorrhagic peptic ulcer 12) Severe complications 13) Patients requiring systemic steroids medication 14) Severe mental disorders 15) Severe drug hypersensitivity 16) Pregnant or lactating women, or women with known or suspected pregnancy and men who want let to pregnancy 17) Patients seems inadequate for this study by investigators 18) Treatment history of a collagen disease or undergoing medical treatment
研究者
相似试验
已完成
2 期
eoadjuvant radiation therapy concurrent with S-1 followed by systemic Gemcitabine therapy for Borderline resectable pancreatic cancer patients; A phase2 studypancreatic cancerJPRN-UMIN000012293Hokkaido Pancreatic Cancer Study Group (HOPS)45
进行中（未招募）
不适用
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II studypatients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoterMedDRA version: 9.1Level: LLTClassification code 10006153Term: Brain tumorEUCTR2008-003003-31-NLEORTC Headquarters108
进行中（未招募）
不适用
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II studypatients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoterMedDRA version: 9.1Level: LLTClassification code 10006153Term: Brain tumorEUCTR2008-003003-31-ATEORTC Headquarters108
进行中（未招募）
不适用
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter a randomized multicenter, open-label, Phase II study. - NDpatients with newly diagnosed glioblastoma without methylation of the MGMT gene promotorMedDRA version: 12.0Level: LLTClassification code 10018336Term: GlioblastomaEUCTR2008-003003-31-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER108
进行中（未招募）
不适用
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II studypatients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoterMedDRA version: 13.1Level: LLTClassification code 10006153Term: Brain tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-003003-31-DEEORTC Headquarters108